|Home | About | Journals | Submit | Contact Us | Français|
With the recent publication of the current journal impact factors, the QJM is now ranked in the top 25 of general medical journals. The journals impact factor increased by 15% compared to the previous year. Another marker of our success is the 25% increase in article downloads whereby 1.5 million articles are downloaded annually from our website (www.qjmed.oxfordjournals.org). One of the keys to this success is the quality of the manuscripts submitted by researchers from around the world. On behalf of the editorial team I would like to thank authors for their continuing strong support.
The QJM has been conscious of publishing state-of-the-art reviews on specific diseases which are clinically focused for the practicing clinician.1–3 Continuing this tradition, we welcome the timely, and authoritative review by Currie & Lipworth published in this issue of the journal in which they provide a practical overview of inhaler therapy in chronic obstructive pulmonary disease (COPD).
There are now an expanding and oftentimes confusing array of inhalers available to patients with airways disease. The authors provide an evidence based overview of the drugs available, describe the evidence supporting their use and highlights practical steps for clinicians with the aim of getting the right inhaler to the right patient.
In analysing the epidemiology of novel psychoactive substance (NPS) use, it is apparent that newer structural modifications of compounds are being introduced into our community on a regular basis. Indeed, in 2014 over ×100 new additional substances were identified in Europe.4,5 For those of us working in acute medicine and dealing with patients overdosing on these substances this raises the question: what is our current knowledge in relation to the most appropriate treatment for these patients?.
Woods and colleagues provide an overview of our sometimes limited knowledge on these newer compounds. Historically, treating overdoses has been very much focused on the specific compound. The authors emphasize that rather than focusing on the specific agent, one should treat which ever of the three broad groups of compounds the drugs belong: (i. stimulant; ii. hallucinogenic or iii. depressant) and the associated symptoms.